Rhea N. Coler

13.9k total citations · 1 hit paper
133 papers, 6.7k citations indexed

About

Rhea N. Coler is a scholar working on Epidemiology, Infectious Diseases and Immunology. According to data from OpenAlex, Rhea N. Coler has authored 133 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Epidemiology, 72 papers in Infectious Diseases and 60 papers in Immunology. Recurrent topics in Rhea N. Coler's work include Tuberculosis Research and Epidemiology (55 papers), Mycobacterium research and diagnosis (31 papers) and Research on Leishmaniasis Studies (26 papers). Rhea N. Coler is often cited by papers focused on Tuberculosis Research and Epidemiology (55 papers), Mycobacterium research and diagnosis (31 papers) and Research on Leishmaniasis Studies (26 papers). Rhea N. Coler collaborates with scholars based in United States, Brazil and Switzerland. Rhea N. Coler's co-authors include Steven G. Reed, Sylvie Bertholet, Susan L. Baldwin, Martin Friede, Thomas S. Vedvick, Antonio Campos‐Neto, Christopher B. Fox, Yasuyuki Goto, Darrick Carter and Mark T. Orr and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and SHILAP Revista de lepidopterología.

In The Last Decade

Rhea N. Coler

125 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New horizons in adjuvants for vaccine development

2008 502 citations Steven G. Reed, Sylvie Bertholet et al. profile →

Peers

Countries citing papers authored by Rhea N. Coler

Since Specialization

Citations

This map shows the geographic impact of Rhea N. Coler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rhea N. Coler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rhea N. Coler more than expected).

Fields of papers citing papers by Rhea N. Coler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rhea N. Coler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rhea N. Coler. The network helps show where Rhea N. Coler may publish in the future.

Co-authorship network of co-authors of Rhea N. Coler

This figure shows the co-authorship network connecting the top 25 collaborators of Rhea N. Coler. A scholar is included among the top collaborators of Rhea N. Coler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rhea N. Coler. Rhea N. Coler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine 2025 ·npj Vaccines ·Lisa A. Jackson, Rhea N. Coler, Gregory A. Deye, Darrick Carter, Sean A. Gray, (unknown), (unknown), Sasha E. Larsen, Christine M. Posavad, Catherine Cox, (unknown), (unknown), Ranjodh Gill, Aravindan Kalyanasundaram, Afzal A. Siddiqui	0
2	T cell–macrophage interactions in tuberculosis: What we've got here is failure to communicate 2025 ·Journal of Internal Medicine ·Rasmus Mortensen, Cecilia S. Lindestam Arlehamn, Rhea N. Coler, Michael Y. Gerner, Delia Goletti, David Lewinsohn, Robert L. Modlin, (unknown), Jyothi Rengarajan, Kevin B. Urdahl, Gerhard Walzl, Samuel M. Behar, Daniel L. Barber	0
3	Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvant 2025 ·ImmunoHorizons ·Sasha E. Larsen, Maham Rais, Valerie A. Reese, (unknown), (unknown), (unknown), (unknown), (unknown), Sean A. Gray, Darrick Carter, Susan L. Baldwin, Rhea N. Coler	0
4	Recombinase-based amplification coupled with lateral flow chromatography for the specific and sensitive detection and identification of Leishmania major in cutaneous leishmaniasis patients 2025 ·Frontiers in Microbiology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Meryem Lemrani, (unknown), K. Kallel, Nabil Haddad, (unknown), Rhea N. Coler, Steven G. Reed, (unknown), Ikram Guizani	0
5	Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals 2024 ·Frontiers in Immunology ·Jiwon Lyu, (unknown), Susan L. Baldwin, Sasha E. Larsen, Xiyuan Bai, David E. Griffith, Véronique Dartois, Threnesan Naidoo, Adrie J. C. Steyn, Rhea N. Coler, Edward D. Chan	6
6	Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial 2023 ·Infectious Diseases and Therapy ·(unknown), Young Ae Kang, Kwang Joo Park, Jae Chol Choi, (unknown), (unknown), (unknown), Boram Lee, (unknown), (unknown), Kwangsoo Jung, (unknown), Valerie A. Reese, Sasha E. Larsen, Susan L. Baldwin, Steven G. Reed, Rhea N. Coler, Hyejon Lee, Sung‐Rae Cho	13
7	Preparation Strategies of the Anti-Mycobacterial Drug Bedaquiline for Intrapulmonary Routes of Administration 2023 ·Pharmaceuticals ·Sara E. Maloney, Ian E. Stewart, Brendan K. Podell, (unknown), Jeffrey B. Mecham, Bryan J. Berube, Susan L. Baldwin, Rhea N. Coler, Anthony J. Hickey	6
8	Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against Mycobacterium avium infection but is ineffective as an adjunct to antibiotic treatment in chronic disease 2022 ·Virulence ·Ju Mi Lee, (unknown), Steven G. Reed, Rhea N. Coler, Jung Joo Hong, Lee‐Han Kim, Wonsik Lee, Kee Woong Kwon, Sung Jae Shin	6
9	Characterizing in vivo loss of virulence of an HN878 Mycobacterium tuberculosis isolate from a genetic duplication event 2022 ·Tuberculosis ·Bryan J. Berube, Sasha E. Larsen, Matthew B. McNeil, Valerie A. Reese, (unknown), (unknown), Tanya Parish, Susan L. Baldwin, Rhea N. Coler	2
10	It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity 2022 ·Frontiers in Immunology ·Sasha E. Larsen, (unknown), Maham Rais, Rhea N. Coler, Susan L. Baldwin	28
11	Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models 2021 ·Scientific Reports ·Sasha E. Larsen, Valerie A. Reese, (unknown), Bryan J. Berube, (unknown), (unknown), Diane Ordway, Marcela Henao‐Tamayo, Brendan K. Podell, Susan L. Baldwin, Rhea N. Coler	20
12	Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection 2020 ·Molecular Therapy — Methods & Clinical Development ·Jesse H. Erasmus, Jacob Archer, (unknown), Amit P. Khandhar, Emily A. Voigt, Brian Granger, Robin Bombardi, Jennifer Govero, Qing Tan, Lorellin A. Durnell, Rhea N. Coler, Michael Diamond, James E. Crowe, Steven G. Reed, Larissa B. Thackray, Robert H. Carnahan, Neal Van Hoeven	83
13	Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines 2017 ·Vaccine ·James D. Allen, Simon O. Owino, Donald M. Carter, Corey J. Crevar, Valerie A. Reese, Christopher B. Fox, Rhea N. Coler, Steven G. Reed, Susan L. Baldwin, Ted M. Ross	20
14	Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy 2012 ·Influenza and Other Respiratory Viruses ·Christopher B. Fox, (unknown), (unknown), James Chesko, Thomas S. Vedvick, Rhea N. Coler, Steven G. Reed, Susan L. Baldwin	15
15	Mycobacterium tuberculosis Rv0198c, a putative matrix metalloprotease is involved in pathogenicity 2011 ·Tuberculosis ·(unknown), Debbie A. Smith, (unknown), Valerie A. Reese, Rhea N. Coler, Tanya Parish	21
16	A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines 2010 ·PLoS ONE ·Rhea N. Coler, Susan L. Baldwin, Narek Shaverdian, Sylvie Bertholet, Jim Reed, Steven G. Reed, Vanitha S. Raman, Xiuhua Lu, (unknown), Kathy Hancock, Jacqueline M. Katz, Thomas S. Vedvick, Malcolm S. Duthie, Christopher H. Clegg, Neal Van Hoeven	124
17	Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys 2009 ·Proceedings of the National Academy of Sciences ·Steven G. Reed, Rhea N. Coler, Wilfried Dalemans, Esterlina V. Tan, Eduardo Canteiro Cruz, Randall J. Basaraba, Ian M. Orme, Yasir A. W. Skeiky, Mark R. Alderson, Karen Cowgill, Jean‐Paul Prieels, Rodolfo M. Abalos, Marie‐Claude Dubois, Joe Cohen, Pascal Mettens, Yves Lobet	137
18	Development of a leishmaniasis vaccine: the importance of MPL 2003 ·Expert Review of Vaccines ·Steven G. Reed, Rhea N. Coler, Antonio Campos‐Neto	49
19	Vaccination with the T Cell Antigen Mtb 8.4 Protects Against Challenge with Mycobacterium tuberculosis 2001 ·The Journal of Immunology ·Rhea N. Coler, Antonio Campos‐Neto, Pamela J. Ovendale, (unknown), Steven P. Fling, Liqing Zhu, Natalya V. Serbina, JoAnne L. Flynn, Steven G. Reed, Mark R. Alderson	80
20	Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family 1999 ·LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) ·Davin C. Dillon, Mark R. Alderson, Craig H. Day, David Lewinsohn, Rhea N. Coler, Teresa Bement, (unknown), Yasir A. W. Skeiky, Ian M. Orme, Allison W. Roberts, Sean Steen, Wilfried Dalemans, Roberto Badaró, (unknown)	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact